Chiesi USA, Inc. is a specialty pharmaceutical company. The Company is focused on commercializing products for the hospital and adjacent specialty markets. Its portfolio of products includes products for the hospital and adjacent specialties, as well as for treating rare diseases. Its product portfolio consists of CARDENE IV (nicardipine hydrochloride) Premixed Injection, BETHKIS (Tobramycin Inhalation Solution), CUROSURF (poractant alfa) Intratracheal Suspension, PERTZYE (pancrelipase) Delayed-Release Capsules, RETAVASE (reteplase, recombinant), ZYFLO (zileuton) Tablets and ZYFLO CR (zileuton) Extended-Release Tablets. The Company is focused on its commercial and development efforts in the hospital and adjacent specialty product sector within the United States pharmaceutical marketplace and generates revenues by marketing approved generic products through its subsidiary, Aristos Pharmaceuticals, Inc.